Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q2- Text added to 2022 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
answer, asserting, avacopan, candidate, Carnation, catastrophic, cell, Center, charge, chemotherapy, constituted, crossover, DAHLIA, declaratory, docetaxel, double, downturn, eculizumab, energy, essentially, extinguishment, flat, heard, hemoglobinuria, Homyk, hundred, immunogenicity, IRA, lung, moved, Napoli, nocturnal, outpace, owe, paroxysmal, passage, PDAB, PNH, pose, profile, promulgated, randomized, reinsurance, reintroduced, reliant, removed, round, satisfaction, Schall, secondary, shareholder, superior, threshold, turn, upholding, upper, withdrew, writ
Valuein 2022 Q2 filing- Value in 2022 Q3 filing
Original filings
Filing view